In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biovail acquires Fuisz Technologies

Executive Summary

Biovail (drug delivery) acquired oral drug delivery company Fuisz Technologies for approximately $245.2mm--about 4 times its 1998 sales--in a two-stage transaction, consisting of about $75.6mm in cash, $78.6mm in stock, and $91mm in debt. Biovail valued Fuisz's approximately 22mm outstanding shares at $7.00 each, a (pr)41% premium to market average.
Deal Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Partial Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies